Metformin, aspirin and statin and risk of cancer: A population-based study in Thailand.

Authors

null

Songporn Oranratnachai

Ramathibodi Hospital, Bangkok, Chiang Mai, Thailand

Songporn Oranratnachai , Nisakorn Thongmung , Piyaporn Phetchoo , Sasivimol Rattanasiri , Ammarin Thakkinstian , Somthawin Lukerak , Prin Vathesatogkit , Narumol Trachu , Piyamitr Sritara , Ekaphop Sirachainan , Thanyanan Reungwetwatttana

Organizations

Ramathibodi Hospital, Bangkok, Chiang Mai, Thailand, Ramathibodi Hospital, Bangkok, Thailand, Trang Hospital, Trang, Thailand, Ramathibodi Hospital Mahidol University, Bangkok, Thailand

Research Funding

Other
National Research Council of Thailand (NRCT).

Background: There were the conflicted results of the association of ASA, metformin or statin and risk of cancer in the previous studies. This is a population-based study in Thai population which aims to investigate the association between these drugs and the risk of cancer. Methods: A population-based retrospective study was done in Electricity Generating Authority of Thailand (EGAT) 1 and 2 databases which have been contained the 27-year and 15-year follow-up time, respectively. This database composed of the clinical characteristics, onset of cancer, and history of interested drugs from the questionnaire, together with the laboratory result from January 2002 to December 2015. We adjusted for age, sex, BMI, smoking and alcohol consumption. The incidence rate ratio (IRR) was estimated for the association between incidence of cancer and interested drugs. Results: Among 2508 and 2731 participants in EGAT1 and 2 respectively, the incidence of cancer was 8.3% in EGAT 1 and 3.5% in EGAT 2. From univariate analysis, use of interested drugs was significant associated with increased risk of cancer with IRR 1.74 (P< 0.001) for ASA, IRR 1.54 (P= 0.043) for metformin and IRR 1.64 (P= 0.001) for statin. In multivariate analysis, only ASA showed significant increasing risk of cancer with IRR 1.47 (P= 0.021). There was a trend increasing risk of cancer for metformin and statin users but not significant. Older age, low BMI, and female significantly associated with higher risk of cancer. In sub-group analysis, age and alcohol were significantly increased risk of GI cancer, while ASA use showed a non-significant trend of increasing risk of GI cancer. HBV infection was a strongly risk factor for hepatobiliary cancer and statin use had a trend lowering risk of this cancer but it was not statistically significant. Metformin also showed a non-significant trend of increasing risk of thoracic cancer. Conclusions: ASA use significantly associated with increasing risk of cancer but metformin and statin showed a trend of higher risk of cancer. These drugs may associate with cancer metabolome pathway which maybe an important role of carcinogenesis. However, ASA, metformin or statin use and risk of cancer is needed to confirm in the longer follow-up and larger cohort.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2019 Breakthrough

Session Type

Poster Session

Session Title

Poster Session A: Access to Care, Diagnostics, Early Detection and Diagnosis, Prevention and Screening, and Surveillance

Track

Access to Care,Diagnostics,Early Detection and Diagnosis,Prevention and Screening,Surveillance

Sub Track

Prevention and Screening

Citation

J Glob Oncol 5, 2019 (suppl 1; abstr 65)

DOI

10.1200/JGO.2019.5.suppl.65

Abstract #

65

Poster Bd #

E5

Abstract Disclosures

Similar Abstracts

Abstract

2019 ASCO Annual Meeting

Metformin, aspirin and statin and risk of cancer: A population-based study in Thailand.

First Author: Songporn Oranratnachai

Abstract

2023 ASCO Annual Meeting

Metformin for chemoprevention of lung cancer in high-risk overweight or obese individuals.

First Author: Isra Nour